The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeuticstm aims to harness next-generation engineering of small ...

WORCESTER ― Victor R. Ambros could have worn anything to Monday morning's press conference at UMass Chan Medical School that ...

MIT study reveals 5-fluorouracil functions by disrupting RNA, not DNA, potentially impacting cancer treatment.

MicroRNAs, or miRNAs, are small, non-coding molecules of RNA. They play an important role in determining how much messenger RNA (mRNA), which carries genetic information, eventually gets translated ...

比如在弥漫大B细胞淋巴瘤 (DLBCL)中外周血清microRNA-21高表达，通过对患者血液中的microRNA-21检测，可以判断DLBCL恶性度，有利于淋巴瘤诊断危险分组及治疗方案选择.

Nobel Prize in Physiology or Medicine has been awarded jointly to Victor Ambros and Gary Ruvkun "for the discovery of ...

Nobel Prize in Physiology or Medicine was awarded jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in regulation.

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.